Moxifloxacin Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin Hydrochloride, the active ingredient in Moxifloxacin Kabi, is a fluoroquinolone presented as an injectable solution for intravenous use. It is employed to treat a variety of serious bacterial infections in adult patients, including community‑acquired pneumonia and intra‑abdominal infections.

GNH USA supplies Moxifloxacin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product meets EU quality standards and is manufactured under strict GMP conditions.

Moxifloxacin Kabi is indicated for several bacterial infections affecting the respiratory, skin and intra‑abdominal systems. - Community‑acquired bacterial pneumonia: effective bacterial eradication and clinical improvement. - Acute bacterial sinusitis: reduces symptoms and clears infection. - Acute bacterial exacerbation of chronic bronchitis: shortens duration and prevents complications. - Skin and skin structure infections: achieves bacterial clearance in complicated cases. - Intra‑abdominal infections: provides broad‑spectrum coverage for polymicrobial infections.

Moxifloxacin Kabi may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort.

Serious or Rare Side Effects: - Tendon rupture: risk of tendonitis or rupture, especially in older patients. - QT interval prolongation: potential cardiac arrhythmia. - Severe hypersensitivity reactions: including anaphylaxis.

When using Moxifloxacin Kabi, clinicians should observe several precautionary measures to minimize risks. - Renal impairment: adjust therapy and monitor renal function. - Hepatic dysfunction: use with caution and monitor liver enzymes. - Concomitant QT‑prolonging drugs: avoid or monitor cardiac rhythm. - History of tendon disorders: avoid use in patients with prior tendon injury. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin Kabi can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption. - Warfarin: may increase anticoagulant effect, monitor INR. - Cyclosporine: increased risk of nephrotoxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of CNS stimulation. - Theophylline: possible increased serum levels. - Oral contraceptives: may reduce effectiveness, advise backup method.